Cargando…
Correction to: Real‑world imatinib mesylate treatment in patients with chronic myeloid leukemia: The importance of molecular monitoring and the early molecular response
| Autores principales: | , , , , , , , , , , , |
|---|---|
| Formato: | Online Artículo Texto |
| Lenguaje: | English |
| Publicado: |
Springer Berlin Heidelberg
2023
|
| Materias: | |
| Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10260693/ https://www.ncbi.nlm.nih.gov/pubmed/37160499 http://dx.doi.org/10.1007/s00277-023-05242-1 |
| _version_ | 1785057858397667328 |
|---|---|
| author | Ferreira, Amanda Pifano Soares Seguro, Fernanda Salles Abdo, Andre Ramires Neder Santos, Fernanda Maria Maciel, Felipe Vieira Rodrigues Nardinelli, Luciana Giorgi, Ricardo Rodrigues Ruiz, Antonio Roberto Lancha Ferreira, Milton Pifano Soares Rego, Eduardo Magalhaes Rocha, Vanderson Bendit, Israel |
| author_facet | Ferreira, Amanda Pifano Soares Seguro, Fernanda Salles Abdo, Andre Ramires Neder Santos, Fernanda Maria Maciel, Felipe Vieira Rodrigues Nardinelli, Luciana Giorgi, Ricardo Rodrigues Ruiz, Antonio Roberto Lancha Ferreira, Milton Pifano Soares Rego, Eduardo Magalhaes Rocha, Vanderson Bendit, Israel |
| author_sort | Ferreira, Amanda Pifano Soares |
| collection | PubMed |
| description | |
| format | Online Article Text |
| id | pubmed-10260693 |
| institution | National Center for Biotechnology Information |
| language | English |
| publishDate | 2023 |
| publisher | Springer Berlin Heidelberg |
| record_format | MEDLINE/PubMed |
| spelling | pubmed-102606932023-06-15 Correction to: Real‑world imatinib mesylate treatment in patients with chronic myeloid leukemia: The importance of molecular monitoring and the early molecular response Ferreira, Amanda Pifano Soares Seguro, Fernanda Salles Abdo, Andre Ramires Neder Santos, Fernanda Maria Maciel, Felipe Vieira Rodrigues Nardinelli, Luciana Giorgi, Ricardo Rodrigues Ruiz, Antonio Roberto Lancha Ferreira, Milton Pifano Soares Rego, Eduardo Magalhaes Rocha, Vanderson Bendit, Israel Ann Hematol Correction Springer Berlin Heidelberg 2023-05-09 2023 /pmc/articles/PMC10260693/ /pubmed/37160499 http://dx.doi.org/10.1007/s00277-023-05242-1 Text en © Springer-Verlag GmbH Germany, part of Springer Nature 2023 https://creativecommons.org/licenses/by/4.0/Open AccessThis article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/ (https://creativecommons.org/licenses/by/4.0/) . |
| spellingShingle | Correction Ferreira, Amanda Pifano Soares Seguro, Fernanda Salles Abdo, Andre Ramires Neder Santos, Fernanda Maria Maciel, Felipe Vieira Rodrigues Nardinelli, Luciana Giorgi, Ricardo Rodrigues Ruiz, Antonio Roberto Lancha Ferreira, Milton Pifano Soares Rego, Eduardo Magalhaes Rocha, Vanderson Bendit, Israel Correction to: Real‑world imatinib mesylate treatment in patients with chronic myeloid leukemia: The importance of molecular monitoring and the early molecular response |
| title | Correction to: Real‑world imatinib mesylate treatment in patients with chronic myeloid leukemia: The importance of molecular monitoring and the early molecular response |
| title_full | Correction to: Real‑world imatinib mesylate treatment in patients with chronic myeloid leukemia: The importance of molecular monitoring and the early molecular response |
| title_fullStr | Correction to: Real‑world imatinib mesylate treatment in patients with chronic myeloid leukemia: The importance of molecular monitoring and the early molecular response |
| title_full_unstemmed | Correction to: Real‑world imatinib mesylate treatment in patients with chronic myeloid leukemia: The importance of molecular monitoring and the early molecular response |
| title_short | Correction to: Real‑world imatinib mesylate treatment in patients with chronic myeloid leukemia: The importance of molecular monitoring and the early molecular response |
| title_sort | correction to: real‑world imatinib mesylate treatment in patients with chronic myeloid leukemia: the importance of molecular monitoring and the early molecular response |
| topic | Correction |
| url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10260693/ https://www.ncbi.nlm.nih.gov/pubmed/37160499 http://dx.doi.org/10.1007/s00277-023-05242-1 |
| work_keys_str_mv | AT ferreiraamandapifanosoares correctiontorealworldimatinibmesylatetreatmentinpatientswithchronicmyeloidleukemiatheimportanceofmolecularmonitoringandtheearlymolecularresponse AT segurofernandasalles correctiontorealworldimatinibmesylatetreatmentinpatientswithchronicmyeloidleukemiatheimportanceofmolecularmonitoringandtheearlymolecularresponse AT abdoandreramiresneder correctiontorealworldimatinibmesylatetreatmentinpatientswithchronicmyeloidleukemiatheimportanceofmolecularmonitoringandtheearlymolecularresponse AT santosfernandamaria correctiontorealworldimatinibmesylatetreatmentinpatientswithchronicmyeloidleukemiatheimportanceofmolecularmonitoringandtheearlymolecularresponse AT macielfelipevieirarodrigues correctiontorealworldimatinibmesylatetreatmentinpatientswithchronicmyeloidleukemiatheimportanceofmolecularmonitoringandtheearlymolecularresponse AT nardinelliluciana correctiontorealworldimatinibmesylatetreatmentinpatientswithchronicmyeloidleukemiatheimportanceofmolecularmonitoringandtheearlymolecularresponse AT giorgiricardorodrigues correctiontorealworldimatinibmesylatetreatmentinpatientswithchronicmyeloidleukemiatheimportanceofmolecularmonitoringandtheearlymolecularresponse AT ruizantoniorobertolancha correctiontorealworldimatinibmesylatetreatmentinpatientswithchronicmyeloidleukemiatheimportanceofmolecularmonitoringandtheearlymolecularresponse AT ferreiramiltonpifanosoares correctiontorealworldimatinibmesylatetreatmentinpatientswithchronicmyeloidleukemiatheimportanceofmolecularmonitoringandtheearlymolecularresponse AT regoeduardomagalhaes correctiontorealworldimatinibmesylatetreatmentinpatientswithchronicmyeloidleukemiatheimportanceofmolecularmonitoringandtheearlymolecularresponse AT rochavanderson correctiontorealworldimatinibmesylatetreatmentinpatientswithchronicmyeloidleukemiatheimportanceofmolecularmonitoringandtheearlymolecularresponse AT benditisrael correctiontorealworldimatinibmesylatetreatmentinpatientswithchronicmyeloidleukemiatheimportanceofmolecularmonitoringandtheearlymolecularresponse |